The regents met at 4 p.m. and broadcasted an audio stream linked to the UM gateway. Participating were Regents Acker, Behm, Bernstein, Brown, Ilitch, Ryder Diggs, Weiser and White. Also, on the call were Vice President Baird, Vice President Churchill, Interim Provost Collins, Interim Vice President Cunningham, Chancellor Dutta, Chancellor Grasso, Executive Vice President Hegarty, Vice President Lynch, Vice President Michels, Vice President Pendse, Executive Vice President Runge, Interim Vice President Taylor and Vice President Wilbanks.

Call to Order and President's Opening Remarks

President Schlissel called the meeting to order. He welcomed everyone to the virtual March Board of Regents meeting and thanked the meeting participants for joining online to continue to protect health and safety while operating the university. He took a roll call of the regents for the record and all were present.

President Schlissel said, “The COVID-19 pandemic has presented an array of challenges, some of which are virtually unprecedented for our university. Members of our community have been affected professionally, personally and sometimes tragically, by the spread and effects of the virus. We also don’t know how long the pandemic will last, which adds to the uncertainties we must face. We’ve been asked to work differently, to innovate on the fly and to change direction quickly based on new guidance from the federal and state governments and our outstanding UM health and safety professionals. We’re also required to isolate and stay at home when possible, often cut off from being
able to support one another face to face, and unable to enjoy the social occasions that enhance quality of life and provide added meaning to our work. But while the pandemic has placed extraordinary demands on our community, the response of our community members has exceeded the extraordinary.

“I want to take the time right now to thank the entire UM family. Our students, faculty, staff and supporters. The UM parents who expressed such concern for not only their children, but all students. The faculty who moved to remote instruction in a matter of days and worked tirelessly to preserve or advance their research. The staff who continue to make Blue Go, especially those called upon for their expertise and efforts in crucial areas as dining, housing, public safety, IT, HR, enrollment, our Maize & Blue Cupboard, and many, many others. And of course, the health professionals on the front lines fighting this epidemic and literally saving lives in our hospitals and clinics. I must really call out the Health System leadership but, not just the leadership but also the doctors, the nurses, the large number of allied health professionals, our maintenance and custodial staff, our security and everybody that works in our Health System. I respect them for their bravery and their commitment to service and I personally find them inspirational. They deserve all of our respect. Thank you to Michigan Medicine. We are very proud of you, very dependent on you, and inspired by you. Thank you all so much.”

President Schlissel continued saying, “Our overarching goal is to prioritize protecting the health of the UM community and making our contribution to slowing the broader spread of the virus while doing our best to continue the pursuit of our teaching, research and patient care missions. Many of the ways we’ve done this are simply
inspiring. Last week Michigan Medicine launched in-house testing for COVID-19 infection, which has rapidly expanded the number of patients who can be properly diagnosed. Our lab is processing results for up to 60 specimens with same-day results and developing the potential to do far more. We are really proud that our pathology team took a test development and approval process that would usually take months and accomplished it in just over a week. I am immensely grateful to the colleagues that made this happen.

“Researchers have ramped down hundreds of labs on campus, positioning them to be ready to return to fully functional status when it’s safe to do so. At the same time, research continues, collecting or analyzing data remotely and diving into work that does not require them to meet in person or on campus. We have organized a suite of tools that support remote work and the ability to keep teaching at UM. Faculty and staff in medicine, public health and other areas have shared their expertise with federal, state and local elected leaders helping them make better decisions about how to protect the public and slow the advance of COVID-19. Interns from our College of Pharmacy made hand sanitizer for our hospital. Leaders in our Human Resources group set up a special paid time-off bank for employees affected by COVID-19. And our wonderful donors are responding as well. They are supporting funds we have set up to help address pressing needs at Michigan Medicine and to provide emergency assistance to our students.

“In 1817, the University of Michigan was established with the promise that we would serve the people through our excellence in education and research. While we still have a long way to go before the pandemic abates, today we are working to deliver on that promise. Together, we are demonstrating the importance of a public research university.
We are rising to the challenge of COVID-19 and continuing to provide education, research and advanced patient care to the people of Michigan. Thank you once again to everyone who has helped continue to make this possible.”

President Schlissel noted that on today’s meeting agenda is the appointment of Susan Collins as interim provost and executive vice president for Academic Affairs until a new provost is named and installed. He said, “We’ll begin thinking about a search process in the months ahead. I want to thank Professor Collins for stepping up and providing outstanding leadership. We are very grateful to benefit from her breadth of experience at the highest levels, including service as former dean of our Gerald R. Ford School of Public Policy, and on the Council on Foreign Relations, and the boards of directors for the Federal Reserve Bank of Chicago and the National Bureau of Economic Research.”

President Schlissel mentioned that efforts such as the Ann Arbor campus’s accreditation and work to improve sexual misconduct policies and procedures continue to move forward despite the challenges and uncertainty created by the pandemic. He brought forward two supplemental appointments for UM leadership positions that will be posted online. The first is the appointment of Rebecca Cunningham as vice president for research. He said, “She has been the interim VP since the departure of Jack Hu. During that time, she has provided excellent leadership in the Office of Research. We continue to be the nation’s top public research university and she has advanced our enterprise through innovative new programming, including our Firearm Injury Prevention Research Initiative, and responding to the shifting federal research landscape. Both Dr. Collins and Dr. Cunningham have led strong preparation efforts and provided the guidance needed to maintain our education and research excellence to every degree possible during the
COVID-19 epidemic. The University of Michigan continues to serve its students, our communities and the world thanks to their terrific work and that of the faculty and staff in their organizations. Thank you and congratulations, Dr. Collins and Dr. Cunningham.

The second supplemental item is the appointment of Martino Harmon as vice president for student life. He said, “Dr. Harmon is currently the senior vice president for student affairs at Iowa State University. Iowa State has more than 33,000 undergraduate and graduate students, and its Student Affairs division includes 800 staff members and 36 departments, including housing, dining, the health center, counseling services and support services for low-income, first generation and students with disabilities. The appointment will result in his return to Ann Arbor, as he served as dean of admission, retention and student life at Washtenaw Community College earlier in his career. Dr. Harmon began his career in student life at the University of Toledo in 1996, serving in increasingly responsible roles over 11 years. He earned bachelor’s, master’s and Ph.D. degrees from the University of Toledo. He will begin at UM on July 1 and Interim Vice President Taylor will remain in the role until then and assist with the transition.”

President Schlissel congratulated Regent Ilitch on her selection as a 2020 Role Model by Alternatives for Girls. He said, “Alternatives for Girls is a Detroit-based nonprofit organization whose mission ‘is to help homeless and high-risk girls and young women avoid violence, teen pregnancy and exploitation, and help them to explore and access the support, resources and opportunities necessary to be safe, to grow strong and to make positive choices in their lives.’ Joining Regent Ilitch as a 2020 Role Model are UM alumna Palencia Mobely, the deputy director and chief engineer of the Detroit Water and Sewage Department; and Laura Chavez Wazeerud-Din of Flagstar Bank.
“Earlier this week the university announced it has contracted with WilmerHale to advance the independent investigation into the late Dr. Robert Anderson. The change in firms will not in any way impede the ability to investigate what happened or compromise the independence of the investigation. WilmerHale will produce a full accounting of the harms caused to former patients by Anderson as well as any institutional failings that allowed him to keep practicing medicine, and that report will be issued to the public and the university simultaneously. WilmerHale is the firm engaged for the investigation into former Provost Martin Philbert as well. That investigation is continuing.

President Schlissel thanked the witnesses and survivors who have come forward to report sexual misconduct in our community. He said, “We have no greater responsibility than the safety of our students, faculty and staff. We must advance the highest standards of conduct and uphold the trust of the public and the members of our community who choose to study, work or seek care at the University of Michigan.”

Instead of a presentation today, the SACUA Annual Report is posted online. President Schlissel thanked Joy Beatty for her service as SACUA chair this past year. He said, “I appreciate her collaboration and commitment to the university as we have confronted very serious and challenging issues. Thank you, Dr. Beatty. And though there is no Central Student Government report this month, I acknowledge the great efforts of Ben Gerstein, who has served as CSG president this past year. In recent weeks, Ben has worked very diligently to represent and assist students affected by the COVID-19 pandemic.”

President Schlissel asked everyone to note the faculty dismissal item, which is item X-2 on the agenda. He said, “The board and I have been presented with the full record
in the matter of the recommended dismissal of David Daniels, professor, in the School of Music, Theatre and Dance. I have determined that Professor Daniels’ conduct is inconsistent with the character of tenure at the University of Michigan and therefore constitutes cause for dismissal under Bylaw Sec. 5.09-1. I therefore recommend the dismissal of Professor Daniels from his tenured position at the University of Michigan, effective immediately. I further recommend that Professor Daniels not be eligible for severance pay under Regents Bylaw 5.10. Today’s vote of the regents will be on both the dismissal and non-eligibility for severance pay.”

Committee Reports:

Finance Audit and Investment Committee

Committee member Regent Weiser reported that he and Regents Acker and Brown met with Kevin Hegarty, executive vice president and chief financial officer; Brian Smith, associate vice president for finance; Cheryl Soper, university controller and director of financial operations; Jeff Moelich, executive director of university audits; and representatives from PricewaterhouseCoopers (PwC) LLP.

The committee discussed a proposal from the university that recommends it be authorized to put into place up to $1 billion of standby letters of credit available for general operating use. Additionally, they reviewed the results of the university’s fiscal 2019 uniform guidance audit performed by PwC and assessed the fiscal 2020 PwC external audit plan and related fees.

Health Affairs Committee

Regent Diggs, chair, reported that she and Regent Behm met with Drs. Dave Spahlinger, University of Michigan Health System president, Jeff Desmond, University
of Michigan Health System chief medical officer, and Mike Mulholland, executive
director. The University of Michigan Medical Group provided an overview of the health
system’s planning and response to the rapidly changing COVID-19 pandemic.

They were then joined by the Michigan Medicine Accountability Task Force Co-
Chairs, Dee Hunt, Michigan Medicine chief human resource officer and Dr. Mark Prince,
chair of the Department of Otolaryngology. They provided an overview of the past,
current and future work of the Michigan Medicine Accountability Task Force.

**Personnel, Compensation and Governance Committee**

Regent Ilitch, chair, reported that she and Regent Bernstein met with Interim
Provost Susan Collins for an update, and also with Chancellors Grasso and Dutta for
updates on the Dearborn and Flint campuses. She said, “The main focus continues to be
the health and safety of all at the University of Michigan. Most are reported to be working
remotely and we have implemented the governor’s Stay Home, Stay Safe order regarding
the COVID-19 virus. Everyone is working hard and is very unified.”

**Minutes.** Vice President Churchill submitted for approval the minutes of the
meeting of February 20, 2020.

**Reports.** Executive Vice President Hegarty submitted the Investment Report,
Plant Extension Report and University Human Resources Report.

**Litigation Report.** Vice President Lynch had no additional report.

**Research Report.** Vice President Cunningham submitted the Report of Projects

**University of Michigan Health System**
Executive Vice President Runge said, “I just want to begin by acknowledging the tremendous service of our physicians, nurses and all staff across our hospitals. They are courageously meeting the challenges of our COVID-19 patients and all of our patients who still need our expertise and care. It is important for all of us to recognize their contributions during this pandemic and the superior care they are providing to our patients, community and each other.

“As of March 26, we have 48 COVID-19 positive adult inpatients and no pediatric inpatients. We have an additional 24 patients under investigation for possible COVID-19. We continue to increase capacity by postponing all non-essential, elective procedures. Based on COVID-19 patient trending in countries that have preceded our outbreak, we have forecasted potential scenarios for inpatient volume on Michigan Medicine’s campus. The scenarios all forecast a growing need for intensive care beds and general isolation rooms for COVID-19 patients. There is a chance, perhaps a likelihood, that our need for patient beds may exceed the capacity of our hospitals in the coming weeks. Given this data, and in conjunction with the university, we have been conducting scenario planning. We know that certain volume triggers may result in the need to use buildings on campus for the care of non-critical COVID-19 patients. We are developing plans that include identifying facility needs, clinical and operational requirements, and staff resources. Currently, our 32-bed RICU for Covid-19 is fully staffed and we are converting some rooms into doubles. We are also caring for patients in negative-pressure rooms in select areas of the hospitals and will continue to do so. More details will be shared as our planning continues.
“I want to say how lucky we are to work with so many leading scientists who we can consult with as we construct treatment options for patients with COVID-19. Our guidelines, developed in conjunction with many individuals in infectious diseases, immunohematology, infectious diseases pharmacy and rheumatology, will continue to evolve based on published data.

“In terms of studies and treatments, we are heavily focused on hydroxychloroquine, remdesivir and tocilizumab for seriously ill patients. We have some other alternative anti-viral options as well. We do not yet know for sure whether any of these treatments provide benefit for these critically ill patients. Research must be done to answer that question and we and others are actively engaged. Early next week we anticipate the startup of two interventional trials for the drug remdesivir and one interventional trial for the drug sarilumab. This has been amazing work by regulatory, contracting, study coordinators and so many people, completing in 3-4 days what is usually six months of work.

“To increase capacity in ambulatory care, we have significantly increased our virtual care program, training more physicians and promoting this option with patients. During this time, we have seen a 300% increase in video visits and a 150% increase in e-visits. We are also consolidating ambulatory services and locations in order to preserve resources and redeploy staff to the most needed areas. We have activated a special HR Staffing Team and created a new process to help departments and units with staffing resource needs. Eligible staff members are being redeployed to areas of highest need.

“We asked the community to donate personal protective equipment such as face masks and other important products to protect health care workers and patients from
COVID-19. We emphasized that we had enough equipment now but we wanted to be prepared in the future with the rising number of cases. We started collecting donations on Saturday and Sunday, and we have been overwhelmed by the generosity of the community. We have received numerous, masks, gloves, gowns, hand sanitizer and other items.

“In addition to the university’s generous 80-hour addition of paid time off for employees in the case of quarantine, isolation or family care needs related to COVID-19, Michigan Medicine has enacted an additional 120 hours, special-use PTO bank for employees who need to quarantine as a result of caring for confirmed COVID-19 patients. This is a very stressful time for all of our staff and we continue to assess what we need to do to better support their well-being. We have made numerous resources available, including direct assistance from our Office of Counseling and Workplace Resilience. At Michigan Medicine, we are committed to deploying all of our resources to help our community overcome the effects of this global pandemic.”

Student Life. Interim Vice President Taylor had no report.

University of Michigan-Dearborn. Chancellor Grasso thanked the UM-Dearborn faculty, staff and students for their dedication, adaptability, sensitivity and significant effort. He said, “We have a terrific team that’s given 110% and has brought life to the aphorism of ‘Mission First, People Always.’ Due to our preparation, we were able to move to online education and remote education as quickly as we did. We did it efficiently, quickly and flawlessly. All of our courses are now offered remotely. We are also moving Summer I and II sessions to remote access, and 84% of faculty and staff are now working remotely. We have a food pantry that is still opened to students and staff
in need that can be accessed by appointment. We’ve created a Student Immediate Relief Fund for which we are asking for financial donations. We have lifted financial holds for summer and fall registration and moved the date for the Winter 2020 balances to May 1. We’re also exploring WiFi hotspots in our parking lots so commuter students who do not have WiFi at home can just pull up their cars and use our parking lot. Our student affairs division has created virtual programming for the students on various topics to keep the sense of community going on campus.

“In the middle of the COVID-19 planning, we were asked to host a Bernie Sanders town hall on March 9, a unique opportunity for the campus community to engage in the democratic process. Our team pulled it all together over the weekend and did a terrific job. The town hall was full and we had an overflow audience of 150 in another location. Also, we had three town halls of our own around strategic planning that attracted 170 faculty members and staff. We received great input on the strategic planning documents to be implemented into our plans.”

**University of Michigan-Flint.** Chancellor Dutta expressed a deep gratitude to the UM-Flint faculty, staff and students who have quickly adjusted and made the transition over to the new format. Faculty and staff have stepped up in numerous ways. He said, “After being asked to leave dorms, some students on our campus did not have access to laptops or computers. This was resolved by providing them with loaner laptops and internet access. This is just one example of how faculty and staff are helping out.” Chancellor Dutta thanked them deeply and noted that as of today there are no positive COVID-19 cases on the UM-Flint campus.
“Faculty and staff are also helping out local and global communities. Assistant Professor Michelle Sahli is working with the public health student organization to collect and distribute soap to people in need through the food banks of Eastern Michigan and in the Flint schools. Professor Robert Buckingham is serving on the World Health Organization COVID-19 Taskforce, a European taskforce that is working to ensure data and correct information is shared between countries to help public health officials and government agencies to make correct decisions for each specific population in Europe. Similar to many institutions, UM-Flint worries about the impact COVID-19 will have on the institution beyond summer but strategies and scenarios are being diligently developed. The national search for provost is on track. It continues virtually and remotely and will hopefully be completed on time.

Central Student Government Report. Central Student Government (CSG) President Gerstein had no additional report.

Voluntary Support. Vice President Baird had no additional report.

Personnel Actions/Personnel Reports. Acting Provost Collins presented a number of personnel actions and reports, along with the supplemental items.

Retirement Memoirs. Vice President Churchill submitted seven retirement memoirs.

Memorials. There were no deaths reported to the regents this month.

Degrees. There are no actions with respect to degrees this month.

Approval of Consent Agenda. On a motion by Regent White, seconded by Regent Ilitch, the regents unanimously approved the consent agenda.

Absolute Return and Alternative Asset Commitments
Executive Vice President Hegarty reported on the university’s follow-on investments with previously approved partnerships with a commitment of $50 million to Partners for Growth Fund VI, L.P.; a commitment of $6.2 million to two Sequoia Capital sponsored funds; a commitment of $50 million to two related Flexpoint Ford sponsored funds; and an additional $15 million to General Catalyst Group IX, L.P.

**University of Michigan-Flint William S. White Building Classroom Renovations**

On a motion by Regent White, seconded by Regent Acker, the regents unanimously approved the project as described and authorized issuing the project for bids and awarding construction contracts provided that bids are within the approved budget.

**Authorization to Sell Real Estate (5728 Whitmore Lake Road, Brighton, Michigan)**

On a motion by Regent White, seconded by Regent Behm, the regents unanimously approved the sale of the property located at 5728 Whitmore Lake Road, Brighton, Michigan for $965,000 upon terms and conditions acceptable to the university, and authorize the executive vice president and chief financial officer to take all appropriate and necessary steps to complete the transaction described above.

**Authorization to Establish Lines of Credit**

Executive Vice President Hegarty said, “Included in the board materials is a request that the board approve a recommendation to establish up to $1B in standby lines of credit for the university’s general operating use to enhance the university’s existing financial safety net. To be clear, the university will not have to draw on these lines and will first look to the existing balance sheet reserves to fund its operations, but in the event of a financial emergency, having the $1B standby lines would be a highly valuable addition to our safety net. Any draw on the lines would essentially become debt of the
university, with a predefined repayment period and interest rates that are likely to be indexed to a liable substitute.”

On a motion by Regent White, seconded by Regent Bernstein, the regents unanimously approved the adoption of the attached resolution authorizing the executive vice president and chief financial officer or associate vice president for finance, or the treasurer to develop the terms, and negotiate and execute the legal documentation for the revolving lines of credit with the assistance of outside legal counsel.

Conflicts of Interest

On a motion by Regent White, seconded by Regent Behm, the regents unanimously approved the following conflict of interest items that fall under the State of Michigan Conflict of Interest Statute through a roll call vote. The following information is provided in compliance with statutory requirements:

Authorize Execution of Investment Agreements Under the MINTS Program for Agita Labs, Inc.

An agreement with the MINTS Program for Agita Labs, Inc. to finance agreements up to a total of $5 million in potential investments (through one or more rounds of financing) under MINTS was approved.

1. The parties to the contract are the Regents of the University of Michigan and Agita Labs, Inc.
2. No use of university services or facilities, nor any assignment of university employees, is obligated or contemplated under the agreements.
3. The pecuniary interest arises from the interest of University of Michigan employee Todd Austin and Valeria Bertacco in Agita Labs, Inc.

Authorization for the University of Michigan to Enter into a License Agreement with a Venture Accelerator Firm Located at the North Campus Research Complex

An agreement with Mekanistic Therapeutics Inc was approved.

1. The parties to the contract are the Regents of the University of Michigan and Mekanistic Therapeutics Inc.
2. The service to be provided is the license of space in the North Campus Research Complex Venture Accelerator located at 1600 Huron Parkway, Ann Arbor, Michigan with access to common area space within the building. The license will use the standard University of Michigan Venture Accelerator license template. The licensee company will pay the rates as stipulated in the attached spreadsheet for the current term and option years as indicated. The licensee company will be responsible for providing monthly updates concerning its business progress to the University of Michigan’s Office of Technology Transfer, and will have access to Office of Technology Transfer personnel for advice concerning obtaining technology assessment, business consulting, technical assistance, capital raising or other business services.

3. The pecuniary interest arises from the fact that University of Michigan employees Judith Leopold and Christopher Whitehead are owners and/or officers of Mekanistic Therapeutics Inc.

Authorization for the University of Michigan to transact with Danielle Nash

An agreement with Danielle Nash was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Zell Lurie Institute and Danielle Nash.

2. The agreement is for a duration of one year at a total cost not to exceed $6,500. Danielle Nash will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in Procurement Services’ standard templates for other similar transactions entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee Danielle Nash is owner of Danielle Nash.

Authorization for the University of Michigan to transact with Historically Black Colleges & Universities-Doctoral Application Prep

An agreement with Historically Black Colleges & Universities-Doctoral Application Prep (HBCU-DAP) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Zell Lurie Institute and Historically Black Colleges & Universities-Doctoral Application Prep.

2. The agreement is for a duration of one year at a total cost not to exceed $6,500. HBCU-DAP will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in Procurement Services’ standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee Sierra Nance is owner of HBCU-DAP.

Authorization for the University of Michigan to transact with Liyang Luo

An agreement with Liyang Luo was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Zell Lurie Institute and Liyang Luo.

2. The agreement is for a duration of one year at a total cost not to exceed $6,500. Liyang Luo will be supplying all the necessary resources and personnel to fulfill this contract.
The remaining base contract terms and conditions are typical to those used in Procurement Services’ standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee Liyang Luo is owner of Liyang Luo.

Authorization for the University of Michigan to transact with Nana Britwum

An agreement with Nana Britwum was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Zell Lurie Institute and Nana Britwum.

2. The agreement is for a duration of one year at a total cost not to exceed $6,500. Nana Britwum will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in Procurement Services’ standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee Nana Britwum is owner of Nana Britwum.

Authorization for the University of Michigan to transact with PeerMinutes

An agreement with PeerMinutes was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Zell Lurie Institute and PeerMinutes.

2. The agreement is for a duration of one year at a total cost not to exceed $6,500. PeerMinutes will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in Procurement Services’ standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employee Anastasija Bergeron is owner of PeerMinutes.

Authorization for the University of Michigan to transact with PuriPod

An agreement with PuriPod was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Zell Lurie Institute and PuriPod.

2. The agreement is for a duration of one year at a total cost not to exceed $6,500. PuriPod will be supplying all the necessary resources and personnel to fulfill this contract. The remaining base contract terms and conditions are typical to those used in Procurement Services’ standard templates for other similar contracts entered into by the regents.

3. The pecuniary interest arises from the fact that University of Michigan employees Nina Serr and Naman Shah are owners of PuriPod.

Subcontract Agreement between the University of Michigan and the Association of Professors of Gynecology & Obstetrics
A subcontract agreement with the Association of Professors of Gynecology & Obstetrics to fund an American Medical Association (prime) project entitled, “Transforming the UME to GME Transition for Obstetrics and Gynecology ‘Right Resident, Right Program, Ready Day One’” (ORSP #19-PAF06329) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Obstetrics and Gynecology and the Association of Professors of Gynecology & Obstetrics.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately five (5) years. The amount of funding support will not exceed $869,431. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Dr. Maya Hammoud is the immediate past president of the board of directors of the Association of Professors of Gynecology & Obstetrics.

Research Agreement between the University of Michigan and Ascentage Pharma Group Corporation, Ltd.

A research agreement with Ascentage Pharma Group Corporation, Ltd. to fund a project entitled, “A Multi-Center, Phase I/II Study of Combination Treatment of APG-1252 with Paclitaxel in Patients with Relapsed/Refractory Small Cell Lung Cancer” (ORSP #20-PAF02618) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Internal Medicine and Ascentage Pharma Group Corporation, Ltd.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $637,265. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Shaomeng Wang is part owner of Ascentage Pharma Group Corporation, Ltd.

Research Agreement between the University of Michigan and Courage Therapeutics, Inc.

A research agreement with Courage Therapeutics, Inc. to fund a project entitled, “Characterization of Courage MC3R agonist peptides” (ORSP #20-PAF05389) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Life
1. The parties to the contract are the Regents of the University of Michigan, its Life Sciences Institute and Courage Therapeutics, Inc.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $2,006,201. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Dr. Roger Cone is part owner of Courage Therapeutics, Inc.

Subcontract Agreement between the University of Michigan and Courage Therapeutics, Inc.

A subcontract agreement with Courage Therapeutics, Inc. to fund an NIH (prime) STTR Phase I project entitled, “Computational Approaches to Drug Discovery at the Melanocortin-3 Receptor” (ORSP #20-PAF04224) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Life Sciences Institute and Courage Therapeutics, Inc.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $115,621. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Dr. Roger Cone is part owner of Courage Therapeutics, Inc.

Sponsored Activity Agreement between the University of Michigan and EVOQ Therapeutics LLC

A sponsored activity agreement with EVOQ Therapeutics LLC to amend an agreement originally approved by the regents to include the proposal entitled, “EVOQ General Services Agreement 2 through 6/30/2021” (ORSP #20-PAF05551) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Pharmaceutical Sciences and EVOQ Therapeutics LLC.

2. The terms of the agreement conform to university policy. The period of performance for the project is extended to June 30, 2021. The amount of funding support will be increased by $50,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees James Moon and Anna Schwendeman are part owners of EVOQ Therapeutics LLC.

Research Agreement between the University of Michigan and The Hope Foundation
A research agreement with The Hope Foundation to fund a project entitled, “Hope CEA: Improving Tolerance of Aromatase Inhibitor Medications in Women with Breast Cancer” (ORSP #20-PAF05372) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Internal Medicine and The Hope Foundation.
2. The terms of the agreement conform to university policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $100,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employee James Rae is the secretary of the board of directors for The Hope Foundation.

Research Agreement between the University of Michigan and The Hope Foundation

A research agreement with The Hope Foundation to fund a project entitled, “Vitamin D Deficiency and Risk of Paclitaxel-induced Peripheral Neuropathy in Patients on SWOG 0221” (ORSP #20-PAF05427) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Clinical Pharmacy and The Hope Foundation.
2. The terms of the agreement conform to university policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $174,920. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employee James Rae is the secretary of the board of directors for The Hope Foundation.

License Agreement between the University of Michigan and Maiqi (Beijing) Technology Co., Ltd.

A license agreement with Maiqi (Beijing) Technology Co., Ltd. to license from the University of Michigan the university’s rights associated with the following technologies was approved: UM OTT File No. 7666 entitled, “MEMS-Based Single Axis Confocal Endomicroscope”; UM OTT File No. 2018-235 entitled, “Ultra-Compact Microsystems-Based Confocal Endomicroscope”; and UM OTT File No. 2018-422 entitled, “Phase Correction for Single Pixel Camera in a Lissajous Pattern.”
1. The parties to the contract are the Regents of the University of Michigan and Maiqi (Beijing) Technology Co., Ltd.

2. Agreement terms include granting Maiqi (Beijing) Technology Co., Ltd. an exclusive license with the right to grant sublicenses in China, Hong Kong, Taiwan and Macau. Maiqi (Beijing) Technology Co., Ltd. will pay a royalty on sales and reimburse patent costs. The university may receive equity in Maiqi (Beijing) Technology Co., Ltd., along with the right to purchase more equity. The university will retain ownership of the licensed technologies and may continue to further develop and use them internally. No use of university services or facilities, nor any assignment of university employees, is obligated or contemplated under the agreement. Standard disclaimers of warranties and indemnification apply, and the agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employees Haijun Li and Gaoming Li are part owners of Maiqi (Beijing) Technology Co., Ltd.

**Subcontract Agreement between the University of Michigan and Mitovation, Inc.**

A subcontract agreement with Mitovation, Inc. to fund an NIH (prime) STTR Phase II project entitled, “Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury (sub from Mitovation-STTR)” (ORSP #20-PAF04972) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Internal Medicine and Mitovation, Inc.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed $301,334. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Thomas Sanderson is part owner of Mitovation, Inc.

**Subcontract Agreement between the University of Michigan and NS Nanotech Inc.**

A subcontract agreement with NS Nanotech Inc. to fund a Department of Energy (prime) STTR Phase I project entitled, “High Efficiency Green and RYGB Direct Emitting LEDs for Down-conservation Free White Light” (ORSP #20-PAF05635) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Electrical and Computer Engineering and NS Nanotech Inc.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately nine (9) months. The amount of funding support will not exceed $100,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employee Zetian Mi is part owner of NS Nanotech Inc.

License Agreement between the University of Michigan and Omniscent, Inc.

A license agreement with Omniscent, Inc. to license from the University of Michigan the university’s rights associated with the following technology was approved:

UM OTT File No. 5618 entitled, “Standardized Scalable Micro GC.”

1. The parties to the contract are the Regents of the University of Michigan and Omniscent, Inc.
2. Agreement terms include granting Omniscent, Inc. an exclusive license with the right to grant sublicenses. Omniscent, Inc. will pay a royalty on sales and reimburse patent costs. The university may receive equity in Omniscent, Inc., along with the right to purchase more equity. The university will retain ownership of the licensed technology and may continue to further develop it and use it internally. No use of university services or facilities, nor any assignment of university employees, is obligated or contemplated under the agreement. Standard disclaimers of warranties and indemnification apply, and the agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employees Yogesh Gianchandani and Yutao Qin are part owners of Omniscent, Inc.

License Agreement between the University of Michigan and Omniscent, Inc.

A license agreement with Omniscent, Inc. to license from the University of Michigan the university’s rights associated with the following technology was approved:

UM OTT File No. 7138 entitled, “Progressive Cellular Architecture for Microfabricated Gas Chromatograph.”

1. The parties to the contract are the Regents of the University of Michigan and Omniscent, Inc.
2. Agreement terms include granting Omniscent, Inc. an exclusive license with the right to grant sublicenses. Omniscent, Inc. will pay a royalty on sales and reimburse patent costs. The university may receive equity in Omniscent, Inc., along with the right to purchase more equity. The university will retain ownership of the licensed technology and may continue to further develop it and use it internally. No use of university services or facilities, nor any assignment of university employees, is obligated or contemplated under the agreement. Standard disclaimers of warranties and indemnification apply, and the agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.
3. The pecuniary interest arises from the fact that University of Michigan employees Yogesh Gianchandani and Yutao Qin are part owners of Omniscent, Inc.

Research Agreement between the University of Michigan and the Osteology Foundation
A research agreement with the Osteology Foundation to fund a project entitled, “Regenerative Medicine Approaches for Periodontal and Dental Implant Reconstruction” (ORSP #20-PAF04785) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Periodontics and Oral Medicine and the Osteology Foundation.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $36,125. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee William Giannobile is the president of the board of directors for the Osteology Foundation.

Research Agreement between the University of Michigan and PP2A Therapeutics Oy

A research agreement with PP2A Therapeutics Oy to amend a research agreement to include the proposal entitled, “Testing of small molecule PP2A activators in cellular systems – Amendment 2” (ORSP #20-PAF06005) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its Department of Internal Medicine and PP2A Therapeutics Oy.

2. The terms of the agreement conform to university policy. The period of performance for the project is extended to December 31, 2020. The amount of funding support will be increased by $100,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Dr. Goutham Narla is part owner of PP2A Therapeutics Oy.

Subcontract Agreement between the University of Michigan and Sarcoma Alliance for Research Through Collaboration

A subcontract agreement with Sarcoma Alliance for Research Through Collaboration to fund a Janssen Scientific (prime) project entitled, “A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging” (ORSP #20-PAF04268) was approved.

1. The parties to the contract are the Regents of the University of Michigan, its
Department of Internal Medicine and Sarcoma Alliance for Research Through Collaboration.

2. The terms of the agreement conform to university policy. The period of performance for the project is approximately nine (9) years. The amount of funding support will not exceed $87,900. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

3. The pecuniary interest arises from the fact that University of Michigan employee Denise Reinke is the president and chief executive officer of Sarcoma Alliance for Research Through Collaboration.

**University of Michigan-Dearborn Bylaws**

On a motion by Regent White, seconded by Regent Weiser, the regents unanimously approved the revised University of Michigan-Dearborn Bylaws, Article IV.

**Statement by Regent Weiser**

Regent Weiser said, “When a tenured faculty member is accused of misconduct, it is a matter that the Board of Regents takes very seriously. The institution of tenure is sacrosanct within any university. It is rare for the board to vote to dismiss a tenured faculty member from the university. This is the first time under the current Bylaw 5.09, enacted more than 60 years ago, that the board has been faced with voting to dismiss a tenured member of the faculty. Because of the strength of the protections of tenure, we have strict bylaws dictating procedures that must be followed if the misconduct is sufficiently serious as to warrant the removal of tenure from the faculty member. At the heart of every decision of the board is the safety and well-being of our students, and the integrity of the instruction to which our students are entitled. When the board sees this jeopardized by a tenured member of the faculty, we believe it is necessary to take the extreme action of dismissal.”

**Public Comment on Agenda Related Item**
The regents heard public comments on Professor David Daniels from: Stephanie Blythe, citizen; Richard Clement, citizen; and Nicholas Phan, alumni.

President Schlissel called for a vote.

**Faculty Dismissal**

On a motion by Regent White, seconded by Regent Acker, the regents unanimously approved the dismissal of Professor David Daniels, School of Music, Theatre and Dance, from his tenured position at the University of Michigan, effective immediately.

**Public Comment**

The regents heard public comments from: Elliott Brannon, student, on social justice; and Jill Hasen, staff, on physician assistants’ union.

Regent Bernstein said, “Jill, I really appreciate you sharing your public comment with us today. I want to thank everybody who has signed up to participate in public comments during this incredibly challenging time for our state and society. Jill, it was wonderful to spend time with you and others who are engaged in the organizing effort on behalf of UM physician assistants. I am speaking as an individual regent at this moment but I am certain that my colleagues share this view. We know that you are heroes on the front lines with everybody at our health system right now in an extraordinary and unprecedented moment in medical care related to this COVID-19 pandemic.

“Speaking as an individual, I want you to know that I fully support your organizing efforts. As I’ve said before to my colleagues and publicly, I also support the ability of all our UM employees to determine and certify their bargaining in a way that enables workers to obtain the protection of collective bargaining. I also would like to say
that in that process the adoption of something commonly referred to as card check should be adopted. This has been done in a dozen states and other municipalities. Lastly, I think the university should adopt or codify a neutrality position with respect to organizing efforts. The university shouldn’t express a positive or negative opinion about such efforts. Again, I applaud your work and the work of your colleagues and most importantly, feel profoundly grateful to you and all the physician assistants and the work they’re doing at this very moment.”

Regent Ryder Diggs said, “As the only physician on the board, Jill, I appreciate your comments today, especially in light of this pandemic that the world is facing, not to mention our state of Michigan. We have a lot of work before us and your 30 years of service at the University of Michigan matters as well as all the efforts of your colleagues, particularly in these weeks. Thank you.”

Regent Brown said, “I would like to reiterate what my colleagues have said. I know there has been so much support on the board for everything that you and your colleagues do and I think the whole country is appreciating it at this time. You are working so hard and fighting for us at the hospitals and we’ll do everything we can to fight for you and your colleagues here on the board at the University of Michigan.”

Public comments continued with Dominic Coletti, student, on COVID-19 housing response; Alysia Treviño, UM-Flint student, on financial support for Flint/Dearborn; Labiba Qazi, UM-Dearborn student, on Dearborn student financial aid; and Cindy Felcher, staff, on physician assistants’ union.
Vice President Churchill acknowledged the efforts of the IT and VPS staff who have staffed this meeting all day in person. Those include Amy Peters, Trena Brannon, JD Jordan, Robert Hays, Erin Katz and Patrick Ryan.

Public comments ended with Megan Williams-Morad, staff on physician assistants’ union.

Regent Behm said, “In this time of crisis, it is awe inspiring to see everyone in the health system do what they are doing and be so supportive of our community.”

Regent Weiser thanked all the speakers on behalf of the board and assured them that they have been heard.

President Schlissel thanked all the speakers, Board of Regents and executive team for having this first remote meeting of his era. He said, “I appreciate the fact that the governance of the university continues despite our approach to public safety around this pandemic. I wish everybody good health and remind you all to practice social distancing, hand washing and the other means you can participate in to stem the spread of this pandemic. Thanks again to our colleagues at Michigan Medicine, all the way up and down the line on behalf of public health. Thank you all very much.”

**Adjournment**

The meeting was adjourned at 5:15 p.m. The next meeting will take place on May 21, 2020.